Eli Lilly and Company (LLY) said on Monday said the U.S. Food and Drug Administration (FDA) has approved a label expansion for Zepbound to include the four-dose single-patient use KwikPen which delivers a full month of treatment in one device.
Lilly added that patients opting for self-pay through LillyDirect, can receive all doses of Zepbound in a KwikPen or as single dose vials, starting at $299 per month for the 2.5 mg dose.
Zepbound is indicated for weight reduction in adults with obesity, those who are overweight with related health conditions, and for treating severe obstructive sleep apnea in adults with obesity.
Lilly shares were trading at 1,042.11, up 3%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.